PARP Inhibitor PJ34 Protects Mitochondria and Induces DNA-Damage Mediated Apoptosis in Combination With Cisplatin or Temozolomide in B16F10 Melanoma Cells

PARP-1 inhibition has recently been employed in both mono- and combination therapies in various malignancies including melanoma with both promising and contradicting results reported. Although deeper understanding of the underlying molecular mechanisms may help improving clinical modalities, the com...

Descripción completa

Detalles Bibliográficos
Autores principales: Cseh, Anna Maria, Fabian, Zsolt, Quintana-Cabrera, Ruben, Szabo, Aliz, Eros, Krisztian, Soriano, Maria Eugenia, Gallyas, Ferenc, Scorrano, Luca, Sumegi, Balazs
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Physiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514236/
https://www.ncbi.nlm.nih.gov/pubmed/31133874
http://dx.doi.org/10.3389/fphys.2019.00538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514236/
https://www.ncbi.nlm.nih.gov/pubmed/31133874
http://dx.doi.org/10.3389/fphys.2019.00538

Ejemplares similares